课题基金 / 基金详情

Design, optimization and mechanism of action of novel HIV-1 entry inhibitors

Design, optimization and mechanism of action of novel HIV-1 entry inhibitors
新型HIV-1进入抑制剂的设计、优化及作用机制
批准号:
9208352
负责人:
Simon Cocklin
金额:
$55.28万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-02-15 至 2018-01-31

项目摘要

项目成果

Simon Cocklin的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive therapeutic approach with broad implications for HIV/AIDS treatment regimens. Combining computer-aided drug design techniques, based upon novel force field representations of compounds, with medicinal chemistry, we have designed and synthesized novel inhibitors of HIV-1 entry, which represent 5 new distinct core chemotypes for the HIV-1 entry inhibitor class. These compounds have low toxicity, nanomolar potency (0.6-100 nM), and are specific to HIV-1. Moreover, we have identified a compound with improved metabolic stability over the current best-in- class entry inhibitor in development. In this study, we propose to further develop these novel entry inhibitor compounds to potencies that are clinically relevant and improve their ADME/PK profiles, whilst also using them as molecular tools to dissect the biology of HIV-1 entry into host cells. The goals of the proposed studies will be accomplished by three discrete but highly integrated specific aims. In Aim 1, the leads will be optimized through in silico approaches, including bioisosteric replacement and prediction of drug-like qualities, coupled to medicinal chemistry. In Aim 2, the antiviral potency, breadth, and specificity of the analogues will be assessed. Evaluation of their toxicity will be performed in parallel. ADME and PK will be assessed via in vitro and in vivo methodologies, and the efficacy will be determined in the humanized bone-liver-thymus (BLT) mouse model of HIV-1 infection. In Aim 3, we will perform detailed mechanism-of-action studies, generate resistance mutants, and investigate the binding site of the compounds using complementary structural techniques including X-ray crystallography, cryo-EM, and negative-stain single-particle electron microscopy. The data from these studies will be used in the future development of next-generation Env-targeted inhibitors with high genetic barriers and unique modes of action. Such compounds will also serve as molecular probes for HIV-1 Env functions, providing novel insight into the complex series of structural transitions through which the Env molecular machine proceeds, in addition to illuminating the details of an elusive site of vulnerability.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3390/molecules23081940
发表时间: 2018-08-03
期刊: Molecules (Basel, Switzerland)
影响因子: --
作者: [Meuser ME, Murphy MB, Rashad AA, Cocklin S]
通讯作者: Cocklin S
Novel anti-HIV compounds targeting the HIV-1 matrix protein
  • 批准号:
    9926276
  • 项目类别:
  • 资助金额:
    $55.51万
  • 财政年份:
    2018
  • 负责人:
    Simon Cocklin
  • 依托单位:
Novel anti-HIV compounds targeting the HIV-1 matrix protein
  • 批准号:
    9750092
  • 项目类别:
  • 资助金额:
    $55.51万
  • 财政年份:
    2018
  • 负责人:
    Simon Cocklin
  • 依托单位:
Discovery and optimization of novel diamine derivatives as HIV-1 entry inhibitors
  • 批准号:
    8707962
  • 项目类别:
  • 资助金额:
    $18.97万
  • 财政年份:
    2013
  • 负责人:
    Simon Cocklin
  • 依托单位:
Discovery and optimization of novel diamine derivatives as HIV-1 entry inhibitors
  • 批准号:
    8603526
  • 项目类别:
  • 资助金额:
    $21.46万
  • 财政年份:
    2013
  • 负责人:
    Simon Cocklin
  • 依托单位:
海外基金